ConforMIS knee implants and instrumentation are designed to address all stages of osteoarthritis, the most common reason for knee replacement surgery.
ConforMIS’ intellectual property includes more than 250 patents and patent applications in the areas of imaging software, image processing, implant design, surgical techniques, instrumentation, and manufacturing, spanning knee, hip, shoulder, spine, and small joints.
With the CE mark certification, all ConforMIS products including the previously launched iUni G2 and iDuo G2 both received the US Food and Drug Administration (FDA) (510K) clearance and CE mark.
ConforMIS will begin commercializing the iTotal CR in Europe in the second half of 2011.